

# **A dimeric thiourea CSA for the enantiodiscrimination of amino acid derivatives by NMR spectroscopy**

Alessandra Recchimurzo,† Cosimo Micheletti,† Gloria Uccello Barretta and Federica Balzano\*

Department of Chemistry and Industrial Chemistry, University of Pisa, via Moruzzi 13, 56124 Pisa, Italy.


†The authors contributed equally to this work.

\*[federica.balzano@unipi.it](mailto:federica.balzano@unipi.it)


**Supporting Information**

## Table of Contents

Nonequivalences of NH and CH protons of amino acid derivatives in the presence of DABCO and <b>BTDA</b> (Figures S1-S2).	S3
1D-ROESY and 1D-TOCSY spectra of ( <i>S</i> )- <b>10</b> / <b>BTDA</b> /DABCO and ( <i>R</i> )- <b>10</b> / <b>BTDA</b> /DABCO mixtures (Figure S3).	S5
<sup>1</sup> H complexation shifts of amino acid derivatives in the presence of DABCO and <b>BTDA</b> (Table S1).	S5
Enantiodiscrimination of <b>10</b> in the presence of <b>BTDA</b> and DABCO or DMAP ( <sup>1</sup> H NMR spectra, Figure S4).	S6
Enantiodiscrimination of <b>10</b> in the presence of <b>BTDA</b> or <b>BTDA</b> /DABCO ( <sup>1</sup> H NMR spectra, Figure S5).	S6
Stoichiometry determination for ( <i>R</i> )- <b>10</b> / <b>BTDA</b> /DABCO and ( <i>S</i> )- <b>10</b> / <b>BTDA</b> /DABCO (Figure S6).	S6
Enantiomeric purity determination (Table S2-S3).	S7
2D gHSQC map of racemic <b>10</b> / <b>BTDA</b> /DABCO (Figure S7).	S8
2D gHMBC map of racemic <b>10</b> / <b>BTDA</b> /DABCO (Figure S8).	S8
1D ROESY spectra (Figures S9-S12).	S9
<sup>1</sup> H NMR (600 MHz, CDCl <sub>3</sub> , 25 °C) and <sup>13</sup> C{ <sup>1</sup> H} NMR (150 MHz, CDCl <sub>3</sub> , 25 °C) spectra of <b>BTDA</b> (Figures S13-S14).	S11
<sup>1</sup> H NMR (600 MHz, CDCl <sub>3</sub> , 25 °C) spectrum of <b>1-5</b> (30 mM) in the presence of 1 equivalent of <b>BTDA</b> (Figures S15-S19)	S13
<sup>1</sup> H NMR (600 MHz, CDCl <sub>3</sub> , 25 °C) spectrum of <b>9-13</b> /DABCO (30 mM, 1:1) in the presence of 1 equivalent of <b>BTDA</b> (Figures S20-S24)	S14




**Figure S1.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>, 25 °C) spectral regions corresponding to NH protons of a 1-to-1 mixture of BTDA (30 mM)/racemic: a) **1**, b) **2**, c) **3**, d) **4**, e) **5**, and of 1-to-1-to-1 mixture BTDA (30 mM)/DABCO/racemic: f) **9**, g) **10**, h) **11**, i) **12**, j) **13**. \*Resonance of CSA.




+ DABCO (9-13)


e) **5**  
R=Ph




j) **13**  
R=Me




d) **4**  
R=i-Pr




i) **12**  
R=i-Pr




c) **3**  
R=Me




h) **11**  
R=i-Bu




b) **2**  
R=i-Pr




g) **10**  
R=Ph




a) **1**  
R=Ph



f) **9**  
R=CH<sub>2</sub>Ph



**Figure S2.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>, 25 °C) spectral regions corresponding to methine protons of a 1-to-1 mixture of BTDA (30 mM)/racemic: a) **1**, b) **2**, c) **3**, d) **4**, e) **5**, and of 1-to-1-to-1 mixture BTDA (30 mM)/DABCO/racemic: f) **9**, g) **10**, h) **11**, i) **12**, j) **13**.




**Figure S3.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 30 mM, 25  $^\circ\text{C}$ ) spectral regions of **10**/**BTDA**/**DABCO** equimolar mixture (a); 1D-ROESY experiments (mix 0.4 s) with selective perturbation of CH in (*S*)-**10**/**BTDA**/**DABCO** (b) and (*R*)-**10**/**BTDA**/**DABCO** (c) equimolar mixtures; 1D-TOCSY experiment of ortho protons of substrate in (*R*)-**10**/**BTDA**/**DABCO** equimolar mixture (d).


**Table S1.** Complexation shifts (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ,  $\Delta\delta = \delta_{\text{mixture}} - \delta_{\text{free}}$ , ppm) of **9-13** (30 mM) in the presence of 1 equivalent of **DABCO** and **BTDA**.

Substrate	$\Delta\delta$ (ppm)			
	pDNB <sup>a</sup>	oDNB <sup>b</sup>	CH <sup>c</sup>	NH
<b>9</b>	-0.181 (R)	-0.204 (R)	+0.147 (R)	-0.057 (R)
	-0.092 (S)	-0.035 (S)	+0.097 (S)	-0.015 (S)
<b>10</b>	-0.283 (R)	-0.255 (R)	+0.174 (R)	+0.230 (R)
	-0.067 (S)	-0.008 (S)	+0.125 (S)	+0.057 (S)
<b>11</b>	-0.254 (R)	-0.198 (R)	+0.092 (R)	-0.089 (R)
	-0.074 (S)	+0.062 (S)	+0.012 (S)	-0.036 (S)
<b>12</b>	-0.206 (R)	-0.195 (R)	+0.090 (R)	+0.092 (R)
	-0.061 (S)	+0.007 (S)	-0.006 (S)	+0.047 (S)
<b>13</b>	-0.234 (R)	-0.198 (R)	+0.154 (R)	+0.195 (R)
	-0.060 (S)	+0.055 (S)	+0.073 (S)	+0.269 (S)


<sup>a</sup>Para proton of DNB moiety. <sup>b</sup>Ortho protons of DNB moiety. <sup>c</sup>Methine proton of chiral center.



**Figure S4.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>, 25 °C) spectral regions corresponding to the *ortho*- and *para*-DNB, NH and methine protons of **10** (30 mM) in 1:1:1 mixture: a) **10**/BTDA/DABCO, b) **10**/BTDA/DMAP. \*indicates CSA signals.



**Figure S5.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>/DMSO-d<sub>6</sub>, 25 °C) spectral regions corresponding to CH proton of **10** (30 mM) in BTDA/**10** (a) and in BTDA/**10**/DABCO (b) mixtures (1:1:1).




**Figure S6.** Stoichiometry determination based on *para* protons of DNB group for *(R)*-**10**/BTDA/DABCO (●) and *(S)*-**10**/BTDA/DABCO (◆) complexes.

**Table S2.** Comparison between the data of actual enantiomeric excess (ee %) of (*S*)-**10**, calculated from the mixed volumes of pure enantiomer stock solutions, and ee (%) of (*S*)-**10** determined by integration of the <sup>1</sup>H-NMR signals relating to the NH proton of **10** in **10**/BTDA/DABCO mixtures


Actual ee (%)	ee by NMR (%)
90	90.26
80	80.52
60	59.72
40	40.26
20	19.76
0	0.12
-20	-20.14
-40	-40.22
-60	-60.46
-80	-80.58
-90	-90.24
-99.4	-99.50

**Table S3.** Enantiomeric excess (ee %) determined by <sup>1</sup>H-NMR integration of signals for substrates **9-13** (30 mM, R:S=99:1, ee 98%) in the presence of BTDA/DABCO (30 mM, 1:1)

	ee by NMR (%)
<b>9</b>	-97.70
<b>10</b>	-98.22
<b>11</b>	-97.86
<b>12</b>	-98.18
<b>13</b>	-98.26




**Figure S7.** 2D gHSQC map (600 MHz, 30 mM, 25 °C, CDCl<sub>3</sub>) of equimolar mixture of racemic **10**/BTDA/DABCO.




**Figure S8.** 2D gHMBC map (600 MHz, 30 mM, 25 °C, CDCl<sub>3</sub>) of equimolar mixture of racemic **10**/BTDA/DABCO.







**Figure S9.**  $^1\text{H}$  NMR spectrum (600 MHz, 30 mM,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) of BTDA (a) and 1D-ROESY experiments (mix 0.4 s) with selective perturbation of  $\text{H}_7$  (b),  $\text{H}_8$  (c),  $\text{H}_9$  (d), and  $\text{H}_{10}$  (e) protons.




**Figure S10.**  $^1\text{H}$ -NMR spectrum (600 MHz, 30 mM,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) of BTDA (a) and 1D-ROESY experiments (mix 0.4 s) with selective perturbation of  $\text{N-H}_2$  (b) and  $\text{N-H}_3$  (c).



**Figure S11.** 1D-ROESY experiments (600 MHz, 30 mM,  $\text{CDCl}_3$ , 25 °C, mix 0.4 s) with selective perturbation of DABCO protons in (*S*)-**10**/BTDA/DABCO (a) and (*R*)-**10**/BTDA/DABCO (b) mixtures (1:1:1).



**Figure S12.**  $^1\text{H}$ -NMR (600 MHz,  $\text{CDCl}_3$ , 30 mM, 25 °C) spectrum of (*S*)-**10**/BTDA/DABCO equimolar mixture (a) and 1D-ROESY experiments (mix 0.4 s) with selective perturbation of  $\text{H}_7$  (b),  $\text{H}_9$  (c),  $\text{H}_8$  (d),  $\text{H}_{10}$  (e), CH (f), NH (g),  $\text{H}_o$  (h),  $\text{H}_{o\text{-DNB}}$  (i),  $\text{H}_{p\text{-DNB}}$  (j) protons.



**Figure S13.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>, 25 °C) spectrum of BTDA.







Figure S14.  $^{13}\text{C}\{^1\text{H}\}$  NMR (150 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of BTDA.




**Figure S15.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **1**/BTDA (30 mM).




**Figure S16.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **2**/BTDA (30 mM).




**Figure S17.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **3**/BTDA (30 mM).




**Figure S18.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **4**/**BTDA** (30 mM).




**Figure S19.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **5**/**BTDA** (30 mM).




**Figure S20.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **9**/**BTDA**/**DABCO** (30 mM).




**Figure S21.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **10**/BTDA/DABCO (30 mM).



**Figure S22.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **11**/BTDA/DABCO (30 mM).



**Figure S23.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25  $^\circ\text{C}$ ) spectrum of equimolar mixture **12**/BTDA/DABCO (30 mM).



**Figure S24.**  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ , 25 °C) spectrum of equimolar mixture **13**/BTDA/DABCO (30 mM).